Cargando…

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

BACKGROUND: The inflammatory bowel disease questionnaire (IBDQ) is a measure of health-related quality of life (QoL), with higher scores indicating greater QoL. In a prior phase 2 study (NCT02589665), mirikizumab, an anti-IL23p19 antibody, demonstrated efficacy and improvement in IBDQ scores in part...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sands, B E, Feagan, B, Gibble, T H, Traxler, K A, Morris, N, Li, X, Schreiber, S, Jairath, V, Armuzzi, A, Jones, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991148/ http://dx.doi.org/10.1093/jcag/gwac036.031

Ejemplares similares

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
por: Sands, Bruce E, et al.
Publicado: (2023)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
por: Danese, S, et al.
Publicado: (2023)

A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
por: Dignass, A, et al.
Publicado: (2023)

A201 EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
por: Travis, S, et al.
Publicado: (2023)

Lucente stella
Publicado: (1995)

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
por: Chua, Laiyi, et al.
Publicado: (2023)

Decreased myocardial perfusion SPECT lung-to-heart ratio: Lucent lungs
por: Wosnitzer, Brian, et al.
Publicado: (2015)

Sistema de acceso a telefonía e Internet, caso de uso de Alcatel- Lucent /
por: Cabrera Arias, Francisco José Manuel
Publicado: (2014)

Endoscopic intranasal frontal sinusotomy: Har-El G, Lucente F. Laryngoscope 105:440, 1995
por: Chow, K.N
Publicado: (1995)

The accuracy of noncontrast spiral computerized tomography in detecting lucent renal stones: A case report and literature review
por: Adwan, Ayman, et al.
Publicado: (2015)

Symmetric, bilateral upper and lower extremity lucent lesions in a patient with Gaucher's disease on enzyme replacement therapy
por: Kuhn, Andrew S., et al.
Publicado: (2020)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Pulmonary sclerosing pneumocytoma presenting a peritumoral halo and an intervening lucent zone on computed tomography: Radiology–pathology correlation
por: Bae, Kyungsoo, et al.
Publicado: (2019)

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION
por: Crowley, E, et al.
Publicado: (2022)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

A144 CHRONIC DSS LEADS TO ALTERED EXPRESSION OF IRAK4/TPL2 PATHWAYS IN UC-COLONIZED MICE
por: Hann, A, et al.
Publicado: (2022)

Mind the gap! The Lucent Line Sign: A Pathognomonic Radiographic Finding in Periprosthetic Hip Fractures Around Cemented Polished Tapered Femoral Stems
por: Maggs, Joanna L, et al.
Publicado: (2021)

Efficacy and safety of lumbrokinase plus aspirin versus aspirin alone for acute ischemic stroke (LUCENT): study protocol for a multicenter randomized controlled trial
por: Chen, Ying, et al.
Publicado: (2022)

A71 POLYP TO ADENOMA CONVERSION FACTOR AS A SURROGATE FOR ADENOMA DETECTION RATE-– FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT
por: Alobaid, S, et al.
Publicado: (2022)

A31 OUTCOMES OF PATIENTS UNDERGOING REPEAT VIDEOCAPSULE ENDOSCOPY (VCE) PRESENTING WITH OBSCURE GASTROINTESTINAL BLEEDING (OGIB)
por: Krahn, T, et al.
Publicado: (2022)

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022)

A135 DO VISCOUS SWALLOWS IMPROVE THE DIAGNOSTIC YIELD OF HIGH-RESOLUTION MANOMETRY?
por: Ricci, M, et al.
Publicado: (2022)

A92 EDUCATIONAL INTERVENTIONS TO IMPROVE ERGONOMIC PERFORMANCE IN GASTROINTESTINAL ENDOSCOPY: A SYSTEMATIC REVIEW
por: Bansal, R, et al.
Publicado: (2022)

A28 TIME-RESTRICTED FEEDING REDUCES INFLAMMATORY BOWEL DISEASE AND IMPROVES EPITHELIUM COLON REGENERATION
por: Carmona Alcocer, V, et al.
Publicado: (2023)

A222 BILIARY ATRESIA IN BRITISH COLUMBIA: THE ROLE OF REFERRAL AGE AND DIAGNOSITIC EVALUATION ON OUTCOME
por: Smyth, M, et al.
Publicado: (2022)

A97 DEVELOPMENT OF PREDICTION MODELS FOR THE TRIAGING OF REFERRALS OF INDIVIDUALS WITH SUSPECTED INFLAMMATORY BOWEL DISEASE TO IMPROVE PROMPT ACCESS TO CARE
por: St-Pierre, J, et al.
Publicado: (2022)

A34 GLUTEN-FREE DIET IMPROVES DYSPEPTIC SYMPTOMS IN PATIENTS WITH TYPE 1 DIABETES IN WHOM CELIAC DISEASE WAS EXCLUDED
por: Miranda, P M, et al.
Publicado: (2022)

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE
por: Lee, S, et al.
Publicado: (2022)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Validation of the Persian version of the inflammatory bowel disease questionnaire (IBDQ) in ulcerative colitis patients
por: Maleki, Iradj, et al.
Publicado: (2015)

A201 A CASE OF SYPHILIS MASQUARADING AS CROHN’S DISEASE
por: Smith, B C, et al.
Publicado: (2022)

A88 PATIENT AND PHYSICIAN PERSPECTIVE OF TELE-HEALTH IN GASTROENTEROLOGY
por: Tomaszewski, M, et al.
Publicado: (2021)

A163 EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD EOSINOPHILS AND DRUG RESPONSE IN CROHN’S DISEASE: A PRELIMINARY REPORT
por: Cai, B, et al.
Publicado: (2022)

A210 HEPATOLITHIASIS IS A FREQUENT AND PROGNOSTIC FINDING IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
por: Jubran, B, et al.
Publicado: (2022)

A260 ACUTE PANCREATITIS IN JORDANIAN CHILDREN
por: Altamimi, E M, et al.
Publicado: (2022)

A125 A NOVEL TECHNIQUE COMBINING EUS AND SPYGLASS DS SYSTEM GUIDANCE FOR BOTH THE DIAGNOSIS AND MANAGEMENT OF AFFERENT LIMB SYNDROME
por: Almousawi, F, et al.
Publicado: (2022)

A155 ASEPTIC ABSCESS SYNDROME IN INFLAMMATORY BOWEL DISEASE: A CASE REPORT
por: Tam, L, et al.
Publicado: (2022)

A29 HIGH DIMENSIONAL SINGLE CELL ANALYSIS OF IL-4 TREATED MACROPHAGES REVEALS A HETEROGENIC PHENOTYPE AND THE ABSENCE OF CD206+ SUBSETS IN CROHN'S DISEASE PATIENTS
por: Callejas, B E, et al.
Publicado: (2023)

A199 UTILIZATION OF MUCUS-DERIVED O-GLYCAN SUGARS BY THE PATHOGEN C. RODENTIUM FACILITATE ITS COLONIZATION OF THE MURINE GUT
por: Mslati, M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_35vqp3vr2i9cvmp465d5n9q74m